Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
Immune checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of metastatic melanoma. However, ICI are often associated with immune-related adverse events (IRAE) such as colitis, hepatitis, pancreatitis, hypophysitis, pneumonitis, thyroiditis, exanthema, nephritis, myositis, encep...
Main Authors: | Marcus Wölffer, Florian Battke, Martin Schulze, Magdalena Feldhahn, Lukas Flatz, Peter Martus, Andrea Forschner |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/2/302 |
Similar Items
-
Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma
by: Charlotte Nübel, et al.
Published: (2023-11-01) -
Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
by: Jean-Matthieu L’Orphelin, et al.
Published: (2023-04-01) -
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
by: Lina María Serna-Higuita, et al.
Published: (2021-12-01) -
Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
by: Alisa Lepper, et al.
Published: (2023-12-01) -
Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
by: Lorena Villa-Crespo, et al.
Published: (2022-02-01)